Vascepa pill contains a concentrated form of fish oil, icosapent ethyl, indication for prevention. The U.S. Food and Drug Administration (FDA) Dec. 13, 2019, approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive therapy to reduce the risk of cardiovascular events in adults with elevated triglyceride levels.
Feature | Pharmaceuticals | Dave Fornell, Editor
FDA Expands Vascepa to Reduce Cardiovascular Events in Elevated Triglyceride Patients

The U.S. Food and Drug Administration (FDA) approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive therapy to reduce the risk of cardiovascular events in adults with elevated triglyceride levels

Home December 16, 2019
Home
impulse dynamics Optimizer for Heart failure.
News | Heart Failure
Impulse Dynamics Secures $80.25 Million Financing

December 12, 2019 — Impulse Dynamics, developer of Optimizer Smart System for delivering CCM therapy, announced the ...

Home December 12, 2019
Home
aspirin bottle
News | Antiplatelet and Anticoagulation Therapies
Low-dose Aspirin May Not Help African Americans Prevent Heart Disease

December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African ...

Home December 12, 2019
Home
Cardiologs
News | ECG
Cardiologs Earns Frost & Sullivan’s New Product Innovation Award

December 12, 2019 — Cardiologs, a global leader in artificial intelligence (AI) cardiology diagnostics, announced today ...

Home December 12, 2019
Home
DiA’s novel solution leverages AI to transform the way clinicians capture and analyze ultrasound images
News | Cardiac Imaging
DiA Joins with IBM Watson Health to Arm Clinicians with its AI-powered Cardiac Ultrasound Software

December 9, 2019 — DiA Imaging Analysis Ltd., an IBM Alpha Zone Accelerator Alumni Startup, announces a collaboration ...

Home December 09, 2019
Home
CAE Healthcare will showcase its mixed reality training solutions for practicing physicians and medical imaging companies for the first time at the Radiological Society of North America (RSNA) 2019 meeting. With technology platforms that integrate modeled human physiology into immersive, augmented reality environments, CAE Healthcare partners with vendors to deliver risk-free training solutions that meet the needs of physicians and equipment providers. #RSNA19 #RSNA2019
News | Virtual and Augmented Reality
Augmented Reality for Radiology and Cardiology Training Demonstrated at RSNA 2019

November 27, 2019 — CAE Healthcare will showcase its mixed reality training solutions for practicing physicians and ...

Home November 27, 2019
Home
A sample of the transcatheter mitral valve replacement (TMVR) devices in development or clinical trials.
Feature | Heart Valve Technology | Saipriya Iyer
Developments in Transcatheter Mitral Valve Replacement

The overwhelming success story for transcatheter aortic valve replacement (TAVR) moving from a science project to ...

Home November 27, 2019
Home
The Philips Lumify hand-held ultrasound technology is an important component of the mobile ECMO unit. Members of the ECMO team use Lumify for real-time visual guidance when inserting tubes in veins and arteries in a process called ECMO cannulation. #RSNA2019 #RSNA19 #POCUS
Feature | Ultrasound Imaging
Handheld Ultrasound Aids First Mobile ECMO Unit in a Pre-hospital Setting

November 26, 2019 — Physicians from the University of New Mexico (UNM) and local emergency responders recently treated a ...

Home November 26, 2019
Home
A key slide from the TRILUMINATE study one-year results showing the improvement in tricuspid regurgitation from basement with treatment using the transcatheter TriClip device.
News | Heart Valve Technology | Dave Fornell, Editor
TriClip Device For Tricuspid Regurgitation Effective at One Year in TRILUMINATE Study

November 26, 2019 — The preliminary one-year results of the TRILUMINATE Pivotal Study for Abbott's TriClip device, a ...

Home November 26, 2019
Home
News | Cardiovascular Clinical Studies
Virtual Study to Track Statin-Related Adverse Events Being Undertaken by University of Connecticut and Hartford Healthcare

November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have ...

Home November 26, 2019
Home
The FDA cleared the IN.PACT AV drug-coated Balloon. Clinical data shows In.Pact AV DCB is Safe, reduces reinterventions and maintains access for end-stage renal disease patients undergoing dialysis
News
FDA Clears Medtronic Drug-Coated Balloon to Treat Arteriovenous Fistula Lesions

The U.S. Food and Drug Administration (FDA) has cleared the Medtronic In.Pact AV drug-coated balloon (DCB) for the treatment of failing arteriovenous (AV) access in patients with end-stage renal disease (ESRD) undergoing dialysis.

Home November 26, 2019
Home
ECG
News | AHA
Artificial Intelligence Examining ECGs Predicts Irregular Heartbeat, Death Risk

November 22, 2019 — Artificial intelligence can examine electrocardiogram (ECG) test results, a common medical test, to ...

Home November 22, 2019
Home
The percentage of women entering the cardiology workforce is low, despite the fact that half of all medical students are women. Despite the low numbers, many women have become luminaries in the field of cardiology, including Dee Dee Wang, M.D., director of advanced cardiovascular imaging at Henry Ford Hospital, pictured here.
Blog | Cardiovascular Business
Women: Cardiology Needs You!

Now, more than ever, the field of cardiology needs women. But as the national need for more cardiologists overall ...

Home November 22, 2019
Home
This is 4MD’s cardiac nuclear imaging analysis software, shown here integrated with a ScImage cardiovascular information system (CVIS). Both companies displayed on the expo floor at ASNC 2019. The software creates a single page report seen here. PET perfusion imaging was a big topics at the conference. #ASNC #ASNC19 #ASNC2019
Feature | Nuclear Imaging | Dave Fornell, Editor
6 Trends in Cardiac Nuclear Imaging at the ASNC 2019 Meeting

There were a few key takeaways from the American Society of Nuclear Cardiology (ASNC) 2019 annual meeting in September, these included...

Home November 22, 2019
Home
The three sites most often used for distal radial artery access are the (1) anatomic snuffbox above the scaphoid (left), (2) adjacent to the snuffbox at the trapezium bone (center), and (3) the first intermetacarpal space (right). The author’s preference is either of the first two options, although good outcomes have been reported with use of the intermetacarpal space.
Feature | Radial Access | Enrique Flores, M.D., RPVI
Incorporating Distal Radial Artery Access Into Clinical Practice

Interest in distal radial artery access (DRA) is growing rapidly. Among the benefits of DRA are the low risk of entry ...

Home November 21, 2019
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now